COLL - NASDAQ
Collegium Pharmaceutical, Inc.
$31.06
+1.9%Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
At a Glance
Live SnapshotCollegium Pharmaceutical, Inc. Fair Value Envelope
Owner Earnings Valuation Tool
Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation
Historical Financial Data
Base year metrics used for projections
Projection Settings
Forecast period and terminal assumptions
DCF Valuation Summary
Calculation flow from present value to intrinsic value per share
Owner Earnings Projections
Operating Cash Flow - Maintenance CapEx = Owner Earnings
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 | Year 7 | Year 8 | Year 9 | Year 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $530.6M | $854.8M | $1.4B | $2.2B | $3.6B | $5.8B | $9.3B | $14.9B | $24.1B | $38.8B |
| Maintenance CapEx | -$560.7K | -$903.3K | -$1.5M | -$2.3M | -$3.8M | -$6.1M | -$9.8M | -$15.8M | -$25.5M | -$41.0M |
| Owner Earnings | $530.0M | $853.9M | $1.4B | $2.2B | $3.6B | $5.8B | $9.3B | $14.9B | $24.1B | $38.8B |
| Discount Factor | 0.926 | 0.857 | 0.794 | 0.735 | 0.681 | 0.630 | 0.583 | 0.540 | 0.500 | 0.463 |
| Present Value | $490.8M | $732.1M | $1.1B | $1.6B | $2.4B | $3.6B | $5.4B | $8.1B | $12.0B | $18.0B |
Related Guides
Continue your COLL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.